R01-CA136753/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2009	2
2010	2
2011	1
2012	2
2014	5
2015	2
2016	3
2017	1
2018	1
2024	0

1

Beyond sipuleucel-T: immune approaches to treating prostate cancer.

Cheng ML, Fong L. Cheng ML, et al. Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi: 10.1007/s11864-013-0267-z. Curr Treat Options Oncol. 2014. PMID: 24402184 Free PMC article. Review.

2

Unmasking the immune recognition of prostate cancer with CTLA4 blockade.

Kwek SS, Cha E, Fong L. Kwek SS, et al. Nat Rev Cancer. 2012 Mar 1;12(4):289-97. doi: 10.1038/nrc3223. Nat Rev Cancer. 2012. PMID: 22378189 Free PMC article. Review.

3

Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.

Lou DY, Fong L. Lou DY, et al. Urol Oncol. 2016 Apr;34(4):182-92. doi: 10.1016/j.urolonc.2013.12.001. Epub 2014 Feb 2. Urol Oncol. 2016. PMID: 24495446 Free PMC article. Review.

4

Immunotherapy for prostate cancer: biology and therapeutic approaches.

Cha E, Fong L. Cha E, et al. J Clin Oncol. 2011 Sep 20;29(27):3677-85. doi: 10.1200/JCO.2010.34.5025. Epub 2011 Aug 8. J Clin Oncol. 2011. PMID: 21825260 Free PMC article. Review.

5

The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.

Friedlander TW, Fong L. Friedlander TW, et al. J Clin Oncol. 2014 Apr 10;32(11):1104-6. doi: 10.1200/JCO.2013.54.7307. Epub 2014 Mar 10. J Clin Oncol. 2014. PMID: 24616311 No abstract available.

6

Developing immunotherapy as legitimate therapy for patients with prostate cancer.

Small EJ, Fong L. Small EJ, et al. J Clin Oncol. 2010 Mar 1;28(7):1085-7. doi: 10.1200/JCO.2009.26.3483. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100956 No abstract available.

7

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Wei XX, et al. Cancer Immunol Res. 2016 Nov;4(11):948-958. doi: 10.1158/2326-6066.CIR-16-0042. Epub 2016 Sep 29. Cancer Immunol Res. 2016. PMID: 27688020 Free PMC article.

8

A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.

Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. Small EJ, et al. Clin Cancer Res. 2015 Sep 1;21(17):3862-9. doi: 10.1158/1078-0432.CCR-15-0079. Epub 2015 Apr 29. Clin Cancer Res. 2015. PMID: 25925891 Clinical Trial.

9

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.

Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. Oh DY, et al. Cancer Res. 2017 Mar 15;77(6):1322-1330. doi: 10.1158/0008-5472.CAN-16-2324. Epub 2016 Dec 28. Cancer Res. 2017. PMID: 28031229 Free PMC article.

10

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.

Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Kwek SS, et al. J Immunol. 2012 Oct 1;189(7):3759-66. doi: 10.4049/jimmunol.1201529. Epub 2012 Sep 5. J Immunol. 2012. PMID: 22956585 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

17 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year